Pharma-Bio Serv (PBSV) EBITDA Margin (2010 - 2026)
Pharma-Bio Serv's (PBSV) quarterly EBITDA Margin came in at 5.35% in Q2 2026, up 942.0% on a YoY basis from 0.51% in Q2 2025, and up 229.94% quarter-over-quarter from 4.12% in Q1 2026.
Powered by 
Analysis
Pharma-Bio Serv (PBSV) EBITDA Margin (2010 - 2026) Analysis & Trends
Pharma-Bio Serv (PBSV) has reported EBITDA Margin for 16 consecutive years, with 5.35% the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, EBITDA Margin rose 942.0% year-over-year to 5.35%; the trailing twelve-month figure through Apr 2026 stood at 4.36% (up 318.0% YoY), and the FY2025 full-year result was 7.08%, up 646.0% from the prior year.
- EBITDA Margin grew to 5.35% in Q2 2026 per PBSV's latest filing, from 4.12% in the prior quarter.
- Across five years, EBITDA Margin topped out at 10.06% in Q3 2023 and bottomed at 18.41% in Q1 2024.
- Historically, EBITDA Margin has averaged 1.88% across 5 years, with a median of 2.58% in 2025.
- The sharpest annual moves came in 2022 and 2024: EBITDA Margin soared 8936 bps in 2022, then slumped 2617 bps in 2024.
- Over 5 years, EBITDA Margin stood at 3.64% in 2022, then slumped by 139 bps to 1.44% in 2023, then plunged by 359 bps to 6.61% in 2024, then gained by 6 bps to 6.2% in 2025, then surged by 186 bps to 5.35% in 2026.
- According to Business Quant data, EBITDA Margin over the past three periods registered 5.35%, 4.12%, and 6.2% for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Accenture | 124.62 Bn | 115.58 Bn | 6.13 Bn | 16.96% |
| 2 | UL Solutions | 14.92 Bn | 14.51 Bn | 417.00 Mn | 18.38% |
| 3 | Gartner | 11.76 Bn | 10.28 Bn | 1.19 Bn | 24.09% |
| 4 | Tetra Tech | 9.19 Bn | 8.96 Bn | 243.21 Mn | 12.50% |
| 5 | Booz Allen Hamilton Holding | 8.76 Bn | 8.22 Bn | 1.46 Bn | 9.96% |
| 6 | Genpact | 6.27 Bn | 5.75 Bn | 490.34 Mn | 14.36% |
| 7 | Korn Ferry | 4.28 Bn | 3.15 Bn | 685.99 Mn | 13.21% |
| 8 | Fti Consulting | 4.20 Bn | 4.04 Bn | 316.27 Mn | 8.56% |
| 9 | Grand Canyon Education | 4.01 Bn | 3.73 Bn | 204.08 Mn | 22.02% |
| 10 | Pharma-Bio Serv | 12.37 Mn | 3.89 Mn | 902,041.00 | 5.35% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Apr 30, 2026 | 5.35% |
| Jan 31, 2026 | -4.12% |
| Oct 31, 2025 | -6.20% |
| Jul 31, 2025 | -15.99% |
| Apr 30, 2025 | -4.07% |
| Jan 31, 2025 | -3.73% |
| Oct 31, 2024 | -6.61% |
| Jul 31, 2024 | -15.79% |
| Apr 30, 2024 | -13.18% |
| Jan 31, 2024 | -18.41% |
| Oct 31, 2023 | -1.44% |
| Jul 31, 2023 | 10.06% |
| Apr 30, 2023 | 8.33% |
| Jan 31, 2023 | 7.75% |
| Oct 31, 2022 | 3.64% |
| Jul 31, 2022 | 7.74% |
| Apr 30, 2022 | 5.65% |
| Jan 31, 2022 | 7.09% |
| Oct 31, 2021 | -85.72% |
| Jul 31, 2021 | 7.23% |